

Dated-12.08.2022

BSE LIMITED

Corporate Relations Department
Phiroze Jeejeebhoy Towers
Dalal Street, Fort
Mumbai-400001
Scrip code: 543264

NATIONAL STOCK EXCHANGE OF INDIA LIMITED

Listing Department
Exchange Plaza, 5th Floor, Plot no. C/1
G Block, Bandra Kurla Complex, Bandra (E)
Mumbai-400051
Scrip Code: NURECA

Subject: Outcome of Board Meeting under Regulation 30 and 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Dear Sir/Madam,

This is to inform you that the Board of Directors of the Company at the Meeting held today i.e. August 12, 2022 (Friday) have approved the unaudited Standalone and Consolidated Financial Results of the Company for the quarter ended June 30, 2022.

Copies of the unaudited Standalone and Consolidated Financial Results along with Limited Review Reports from the Company's Statutory Auditors are enclosed herewith.

Presentation on financial results for the quarter ended June 30, 2022 is also enclosed.

The Board Meeting commenced at 6:00PM and concluded at 6:45PM.

This is for your kind information and records please.

Thanking You,

Yours Sincerely,
For Nureca Limited

Chetna Anand

(Chetna Anand)

Company Secretary & Compliance Officer



NURECA LIMITED

Correspondence Office : SCO 6-7-8, 1st Floor, Madhya Marg, Sector 9-D, Chandigarh 160009
Registered Office : 101 Office Number, Udyog Bhavan, 1st Floor, Sonawala Lane, Goregaon East,
Mumbai City Maharashtra - 400063

Phone No. +91-172-5292900 CIN L24304MH2016PLC320868

NURECA LIMITED

Office Number 101, 1st Floor Udyog Bhavan Sonawala Lane, Goregaon (East), Mumbai - 400063, Maharashtra, India
 Tel: +91 -172-5292900, E-mail: cs@nureca.com, Website: www.nureca.com
 Corporate Identification Number: L24304MH2016PLC320868

(Amount in INR million, unless otherwise stated)

Statement of Unaudited Standalone Financial Results for the quarter ended 30 June 2022

Sr. No.	Particulars	Quarter ended		Year ended	
		30 June 2022 (Unaudited)	31 March 2022 (Audited) Refer note 2	30 June 2021 (Unaudited)	31 March 2022 (Audited)
1	Revenue from operations	260.60	410.80	1,194.82	2,555.49
2	Other income	11.75	17.14	21.39	77.20
3	Total income (1+2)	272.35	427.94	1,216.21	2,632.69
4	Expenses				
	Purchase of stock-in-trade	126.98	201.92	496.78	1,595.34
	Changes in inventories of stock-in-trade	48.38	56.82	(2.35)	(269.16)
	Employee benefits expense	41.89	30.02	25.12	98.31
	Finance costs	1.29	2.78	2.17	7.31
	Depreciation and amortization expense	5.90	5.71	1.46	14.32
	Other expenses	98.29	147.36	204.88	573.27
	Total expenses	322.73	444.61	728.06	2,019.39
5	(Loss)/profit before income tax (3-4)	(50.38)	(16.67)	488.15	613.30
6	Tax expense				
	- Current tax	-	(8.24)	127.51	155.70
	- Deferred tax (credit)/charge	(11.71)	3.23	(0.89)	4.51
7	Net (loss)/profit after income tax (5-6)	(38.67)	(11.66)	361.53	453.09
8	Other comprehensive income/(expense)				
A	(i) Item that will not be reclassified to profit or loss	0.48	1.75	0.03	1.90
	(ii) Income tax relating to items that will not be reclassified to profit or loss	(0.12)	(0.44)	(0.01)	(0.48)
B	(i) Item that will be reclassified to profit or loss	-	-	-	-
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-
9	Total comprehensive (loss)/income for the period/year (7+8)	(38.31)	(10.35)	361.55	454.51
10	(Loss)/earnings per share of Rs. 10 each - Basic and diluted (in rupees) (not annualized)	(3.87)	(1.17)	36.15	45.31
11	Paid-up equity share capital (Face value of share - Rs.10 each)	100.00	100.00	100.00	100.00
12	Reserve (excluding revaluation reserve)				1,937.43
	See accompanying notes to the unaudited standalone financial results				

NURECA LIMITED

Correspondence Office : SCO 6-7-8, 1st Floor, Madhya Marg, Sector 9-D, Chandigarh - 160009
 Registered Office : 101 Office Number, Udyog Bhavan, 1st Floor, Sonawala Lane, Goregaon East,
 Mumbai City Maharashtra - 400063

Phone No. +91-172-5292900 CIN L24304MH2016PLC320868




NURECA LIMITED

Office Number 101, 1st Floor Udyog Bhavan Sonawala Lane, Goregaon (East), Mumbai - 400063, Maharashtra, India
Tel: +91 -172-5292900, E-mail: cs@nureca.com, Website: www.nureca.com
Corporate Identification Number: L24304MH2016PLC320868

Notes to the unaudited standalone financial results:

- 1 The above unaudited standalone financial results for the quarter ended 30 June 2022 as reviewed by the Audit Committee, have been approved at the meeting of the Board of Directors held on 12 August 2022. The limited review report of the Statutory Auditors is being filed with the BSE Limited and National Stock Exchange of India Limited. For more details, visit the investor relation section of our website www.nureca.com and financials results at corporate section at www.bseindia.com and www.nseindia.com.
- 2 The figures for the last quarter ended 31 March 2022, as reported in these unaudited standalone financial results are the balancing figures between audited figures in respect of the full financial year and the published year to date figures up to the end of third quarter of the previous financial year i.e. 31 December 2021, which had only been reviewed and not subjected to audit.
- 3 The business of the Company falls within single line of business i.e. business of home healthcare and wellness products
- 4 On 20 May 2022, the Company has invested INR 17.5 million on right issue basis in its wholly owned subsidiary i.e. Nureca Technologies Private Limited.

For and on behalf of Board of Directors of
Nureca Limited



Saurabh Goyal
(Managing Director)
DIN : 00136037

Place: Chandigarh
Date: 12 August 2022

NURECA LIMITED

Correspondence Office : SCO 6-7-8, 1st Floor, Madhya Marg, Sector 9-D, Chandigarh 160009
Registered Office : 101 Office Number, Udyog Bhavan, 1st Floor, Sonawala Lane, Goregaon East,
Mumbai City Maharashtra - 400063

Phone No. +91-172-5292900 CIN L24304MH2016PLC320868

NURECA LIMITED

Office Number 101, 1st Floor Udyog Bhavan Sonawala Lane, Goregaon (East), Mumbai - 400063, Maharashtra, India
Tel: +91 -172-5292900, E-mail: cs@nureca.com, Website: www.nureca.com
Corporate Identification Number: L24304MH2016PLC320868

(Amount in INR million, unless otherwise stated)

Statement of Unaudited Consolidated Financial Results for the quarter ended 30 June 2022

Sr. No.	Particulars	Quarter ended		Year ended	
		30 June 2022 (Unaudited)	31 March 2022 (Audited) Refer note 2	30 June 2021 (Unaudited)	31 March 2022 (Audited)
1	Revenue from operations	255.28	410.49	1,194.82	2,555.48
2	Other income	11.71	17.10	21.39	76.95
3	Total income (1+2)	266.99	427.59	1,216.21	2,632.43
4	Expenses				
	Purchase of stock-in-trade	128.86	202.08	496.78	1,595.51
	Changes in inventories of stock-in-trade	41.95	56.71	(2.35)	(269.27)
	Employee benefits expense	42.79	30.76	25.15	99.14
	Finance costs	1.35	2.85	2.19	7.41
	Depreciation and amortization expense	6.07	5.92	1.55	14.82
	Other expenses	98.97	148.32	204.31	575.01
	Total expenses	319.99	446.64	727.63	2,022.62
5	(Loss)/profit before income tax (3-4)	(53.00)	(19.05)	488.58	609.81
6	Tax expense				
	- Current tax	-	(8.24)	127.51	155.70
	- Deferred tax	(11.71)	3.23	(0.89)	4.51
7	Net (loss)/profit after income tax (5-6)	(41.29)	(14.04)	361.96	449.60
8	Other comprehensive income/(expense)				
A	(i) Item that will not be reclassified to profit or loss	0.48	1.75	0.03	1.90
	(ii) Income tax relating to items that will not be reclassified to profit or loss	(0.12)	(0.44)	(0.01)	(0.48)
B	(i) Item that will be reclassified to profit or loss	(0.02)	(0.01)	-	(0.01)
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-
9	Total comprehensive (loss)/income for the period/ year (7+8)	(40.95)	(12.74)	361.98	451.01
10	(Loss)/earnings per share of Rs. 10 each - Basic and diluted (in rupees) (not annualized)	(4.13)	(1.40)	36.20	44.96
11	Paid-up equity share capital (Face value of share - Rs.10 each)	100.00	100.00	100.00	100.00
12	Reserve (excluding revaluation reserve)				1,931.98
	See accompanying notes to the unaudited consolidated financial results				



NURECA LIMITED

Correspondence Office : SCO 6-7-8, 1st Floor, Madhya Marg, Sector 9-D, Chandigarh 160009
Registered Office : 101 Office Number, Udyog Bhavan, 1st Floor, Sonawala Lane, Goregaon East,
Mumbai City Maharashtra - 400063

Phone No. +91-172-5292900 CIN L24304MH2016PLC320868

NURECA LIMITED

Office Number 101, 1st Floor Udyog Bhavan Sonawala Lane, Goregaon (East), Mumbai - 400063, Maharashtra, India
Tel: +91 -172-5292900, E-mail: cs@nureca.com, Website: www.nureca.com
Corporate Identification Number: L24304MH2016PLC320868

Notes to the unaudited consolidated financial results:

- 1 The above unaudited consolidated financial results for the quarter ended 30 June 2022 as reviewed by the Audit Committee, have been approved at the meeting of the Board of Directors held on 12 August 2022. The limited review report of the Statutory Auditors is being filed with the BSE Limited and National Stock Exchange of India Limited. For more details, visit the investor relation section of our website www.nureca.com and financials results at corporate section at www.bseindia.com and www.nseindia.com.
- 2 The figures for the last quarter ended 31 March 2022, as reported in these unaudited consolidated financial results are the balancing figures between audited figures in respect of the full financial year and the published year to date figures up to the end of third quarter of the previous financial year i.e. 31 December 2021. which had only been reviewed and not subjected to audit.
- 3 The business of the Company falls within single line of business i.e. business of home healthcare and wellness products
- 4 On 20 May 2022, the Company has invested INR 17.5 million on right issue basis in its wholly owned subsidiary i.e. Nureca Technologies Private Limited.

For and on behalf of Board of Directors of
Nureca Limited



Saurabh Goyal
(Managing Director)
DIN : 00136037

Place: Chandigarh
Date: 12 August 2022

NURECA LIMITED

Correspondence Office : SCO 6-7-8, 1st Floor, Madhya Marg, Sector 9-D, Chandigarh 160009
Registered Office : 01 Office Number, Udyog Bhavan, 1st Floor, Sonawala Lane, Goregaon East,
Mumbai City Maharashtra - 400063

Phone No. +91-172-5292900 CIN L24304MH2016PLC320868

B S R & Co. LLP

Chartered Accountants

Unit No. A505 (A),
5th Floor, Plot No.178-178A,
Industrial & Business Park,
Phase -1, Chandigarh-160002

Telephone: +91 172 664 4000
Fax: +91 172 664 4004

Limited Review Report on unaudited standalone financial results of Nureca Limited for the quarter ended 30 June 2022 pursuant to Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015


To the Board of Directors of Nureca Limited

1. We have reviewed the accompanying Statement of unaudited standalone financial results of Nureca Limited ("the Company") for the quarter ended 30 June 2022 ("the Statement").
2. This Statement, which is the responsibility of the Company's management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. Our responsibility is to issue a report on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
4. Attention is drawn to the fact that the figures for the three months ended 31 March 2022 as reported in these unaudited standalone financial results are the balancing figures between audited figures in respect of the full previous financial year and the published year to date figures up to the third quarter of the previous financial year. The figures up to the end of the third quarter of previous financial year had only been reviewed and not subjected to audit.
5. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with applicable accounting standards and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For B S R & Co. LLP

Chartered Accountants

Firm's Registration No.:101248WW-100022



Gaurav Mahajan

Partner

Membership No.: 507857

UDIN:22507857AOWMZN3842

Chandigarh

12 August 2022

Registered Office

B S R & Co. (a partnership firm with Registration No. BA61223) converted into B S R & Co. LLP (a Limited Liability Partnership with LLP Registration No. AAB-8181) with effect from October 14, 2013

14th Floor, Central B Wing and North C Wing, NESCO IT Park 4, NESCO Center, Western Express Highway, Goregaon (East) Mumbai - 400063

BSR & Co. LLP

Chartered Accountants

Unit No. A505 (A),
5th Floor, Plot No.178-178A,
Industrial & Business Park,
Phase -1, Chandigarh-160002

Telephone: +91 172 664 4000
Fax: +91 172 664 4004

Limited Review Report on unaudited consolidated financial results of Nureca Limited for the quarter ended 30 June 2022 pursuant to Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To the Board of Directors of Nureca Limited

1. We have reviewed the accompanying Statement of unaudited consolidated financial results of Nureca Limited ("the Parent"), and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group") for the quarter ended 30 June 2022 ("the Statement"), being submitted by the Parent pursuant to the requirements of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('Listing Regulations').
2. This Statement, which is the responsibility of the Parent's management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the Securities and Exchange Board of India under Regulation 33(B) of the Listing Regulations, to the extent applicable.

4. The Statement includes the results of the following entities :
 - a. Nureca Limited- Parent Company (incorporated in India)
 - b. Nureca INC- Subsidiary Company (incorporated in U.S.A.)
 - c. Nureca Healthcare Private Limited- Subsidiary Company (incorporated in India)
 - d. Nureca Technologies Private Limited, India- Subsidiary Company (incorporated in India)
5. Attention is drawn to the fact that the figures for the three months ended 31 March 2022 as reported in these unaudited consolidated financial results are the balancing figures between audited figures in respect of the full previous financial year and the published year to date figures up to the third quarter of the previous financial year. The figures up to the end of the third quarter of previous financial year had only been reviewed and not subjected to audit.
6. Based on our review conducted and procedures performed as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

B S R & Co. LLP


7. The Statement includes the interim financial information of three subsidiaries which have not been reviewed, whose interim financial information reflect total revenues (before consolidation adjustment) of Rs. Nil, total net (loss) after tax (before consolidation adjustment) of Rs. (2.62 million) and total comprehensive loss (before consolidation adjustment) of Rs. (2.62 million) for the quarter ended 30 June 2022, as considered in the Statement. According to the information and explanations given to us by the Parent's management, these interim financial information are not material to the Group.

Our conclusion is not modified in respect of this matter.

For B S R & Co. LLP

Chartered Accountants

Firm's Registration No.: 101248W/W-100022



Gaurav Mahajan

Partner

Chandigarh

12 August 2022

Membership No.: 507857

UDIN:22507857AOWNZQ4157

NUREÇA

Think.
Feel.
Create.



+ Earnings Presentation
August 2022

Disclaimer

The Presentation is to provide the general background information about the Company's activities as at the date of the Presentation. The information contained herein is for general information purposes only and based on estimates and should not be considered as a recommendation that any investor should subscribe / purchase the company shares. The Company makes no representation or warranty, express or implied, as to, and does not accept any responsibility or liability with respect to, the fairness, accuracy, completeness or correctness of any information contained herein.

This presentation may include certain "forward looking statements". These statements are based on current expectations, forecasts and assumptions that are subject to risks and uncertainties which could cause actual outcomes and results to differ materially from these statements. Important factors that could cause actual results to differ materially from our expectations include, amongst others, general economic and business conditions in India and abroad, ability to successfully implement our strategy, our research & development efforts, our growth & expansion plans and technological changes, changes in the Indian and international interest rates, change in laws and regulations that apply to the healthcare industry, increasing competition, changes in political conditions in India. Neither the company, nor its Directors and any of the affiliates or employee have any obligation to update or otherwise revise any forward-looking statements. The readers may use their own judgment and are advised to make their own calculations before deciding on any matter based on the information given herein.

No part of this presentation may be reproduced, quoted or circulated without prior written approval from Nureca Ltd.

NURECA,
is a leading Digital
healthcare and wellness
Solutions provider



CHRONIC
DISEASES



LIFESTYLE
& FITNESS



ORTHO CARE



MOTHER
& BABY



NUTRITION

Our
Focus
Areas

2021

Listed On Stock
Exchanges

₹ 34 CR

GMV For Q1FY23

₹ 27 CR

Total Revenue For
Q1FY23

50+

USFDA Approved
Products

₹ (5) CR

EBITDA For Q1FY23

₹ (4) CR

PAT For Q1FY23

03

Established Brands

DrTrust DR PHYSIO trumom

210+ SKUS


Respiratory,
Physiotherapy,
Cardiac, Diabetes
And Mother & Child
Care

Our growing customer base

CUSTOMER BASE

(CUMULATIVE)*


(000')



STEADY

IMPROVEMENT IN REPEAT CUSTOMER

Returning visitors to our website



Our customer base has grown exceptionally over the last 4 years which is a result of remarkable quality of our products that led to word-of-mouth marketing by our loyal customer base. Currently, most of our products enjoy 4+ Star ratings out of 5-star ratings across e-commerce platform.


At Nureca, we have a focused marketing strategy to grow our brands and our advertisement expenditure in the range of 3-5% of our revenue which lower compared to the Industry average.

*Gross Market Volume

Financial Updates


GMV

(INR mn)



Operating Revenue

(INR mn)




- ✓ GMV of Q1'FY23 stood at Rs. 338 mn as compared to Rs. 1627 Mn in Q1'FY22, decrease of 79%
- ✓ Operating Revenue was Rs. 255 mn in Q1'FY23 as compared to Rs. 1,195 in Q1'FY22, decrease of 79%
- ✓ Overall, demand has seen a dip in Q1'FY23 as compared to the same quarter last year, which had seen a huge surge in demand due to Covid-19
- ✓ Our Gross margins in Q1'FY23 were impacted due to lower demand, inflation in input cost, currency fluctuation as well as inflationary pressure in other non-core costs such as packaging, transport, etc.
- ✓ Our employee cost has increased as compared to the same quarter last year due to aggressive talent acquisition across the business functions and verticals majorly for app development and expansion of Offline distribution network.
- ✓ Other expenses are lower in Q1'FY23 by 52%, in line with the top line.
- ✓ Overall, EBITDA was Rs. (46) mn in Q1'FY23, lower by 109% and PAT stood at Rs. (41) mn, lower by 111%


Key Performance Indicators

EBITDA & EBITDA MARGIN


(INR mn)



EPS




PAT & PAT MARGIN



Return Ratios

(INR mn)



Note: ROCE derived on basis of average equity and average capital employed


Financials – Income Statement

(INR mn)

Particulars	Q1 'FY23	Q1 'FY22	Q4 'FY22	Q1 'FY23 vs Q4 'FY22	Q1 'FY23 vs Q1 'FY22
Revenue from operations	255	1,195	410	-38%	-79%
Other Income	12	21	17	-32%	-45%
Total Revenue	267	1,216	428	-38%	-78%
Cost of Goods Sold	171	494	259	-35%	-65%
Employee benefits expense	43	25	31	39%	70%
Other expenses	99	204	148	-33%	-52%
Total Expenses	313	724	438	-29%	-57%
EBITDA	-46	492	-10	328%	-109%
Finance Cost	1	2	3	-53%	-38%
Depreciation	6	2	6	3%	292%
PBT	-53	489	-19	170%	-111%
Current tax	-	128	-8	-100%	-100%
Deferred tax	-12	-1	3	-483%	1216%
PAT	-41	362	-14	178%	-111%

Offline expansion – Progressing steadily

Offline Distributors



160+
Distributors

9,000+
Retail outlets
covered

22
States & UTs
covered

Nureca's Products now available at :



Mumbai



Bengaluru




Chennai

+9000 other retail outlets across India

Expanding Our Presence In Wellness And Preventive Healthcare Market

Strong Product Pipeline



SKUs launched till FY22 Product launched in FY22 Product Launched / In Pipeline for FY23 Expected Product basket In FY23

- We launched 4 SKUs in Q1FY23 and 21 SKUs are in pipeline, to be launched in FY23.
- Under the brand "Trumom[®]", we have launched Organic Baby Hair Oil and Organic Baby Massage Oil.
- During the quarter, we added new features and improvements to our Dr. Trust 360 platform to improve user experience. All our devices are now successfully integrated with Dr. Trust 360 platform leading to a seamless flow of user data from our products to the platform. This has now enabled better virtual doctor consultations due to the availability of the different sets of data in one place.

New Product Launches

Trumom® - Organic Baby Massage Oil and Organic Baby Hair Oil

We have launched Organic Baby Massage Oil and organic Baby Hair Oil under our brand "Trumom" to target the conscious mothers who are concerned about products that touch their baby's delicate skin.

Enriched with Organic ingredients, these products are dermatologically tested, Australian certified toxic free, MADE SAFE, Allergy Free certified, Cruelty free and Vegan by Safe Cosmetics Australia.

These oil contains balanced gentle formulations made of organic oils, which are completely safe for babies.

These Products are available in 100 ml packaging.



Organic Baby Hair Oil

Organic Baby Massage Oil

New Product Launches (Cont'd)



Dr Trust® Hearing Amplifier

Our next launch is a cutting-edge hearing technology that improves hearing by making sound audible to a person with hearing loss. Designed with upgraded smart chip, this tiny device disappears behind the ear and supports excellent sound quality. Battery operated technology incorporates 4 level of volume and is ISO and ROHS certified. Users can hear clear sound in the most challenging environment with NO harmful radiations, whistling, echo & buzzing. 3 different size ear buds are added to make it suitable for everyone.

Smart Products Portfolio – DrTrust 360

*Our devices are clinically accurate
USFDA & CE Approved



Body composition scales



BP monitors



Glucometers



ECG monitor



Smartwatches

Health metrics captured from devices:

Weighing scale*

- Bone Mass
- BMI & BMR
- Subcutaneous Fat
- Body Fat %
- Muscle Mass & Rate
- Protein Mass
- Visceral Fat
- Body Water %
- Metabolic Age
- Age
- Height

BP Monitor*

- Systolic BP
- Diastolic BP
- Pulse Rate
- Age
- Height
- Body weight

Glucometer*

- Fasting
- After Meal
- Before Meal
- Random
- Age
- Height
- Body weight

ECG monitor*


- Electrocardiogram
- Heart rhythm
- Heartbeat rate
- Age
- Height
- Body weight

Smartwatches

- Health Monitoring
- Body Temperature
- SpO2
- Heart Rate
- Blood Pressure
- HRV & Stress Level
- Tracking fitness with multisport mode

Our AI driven platform –

DrTrust 360






DrTrust 360

Manage Not Monitor

The No. 1 App For A Holistic Health Management Experience.
Don't just Monitor Your Health,
Manage It With Dr Trust 360.


Syncs With




DrTrust 360


SMART SENSEI TECHNOLOGY




One app for all Dr Trust Smart Devices



Stay connected with doctors with easy data sharing







Clinically approved holistic health recommendations




Easy to use technology with class leading features

Syncs With

DrTrust 360



1 APP 360° Solutions

The future of smart healthcare reimagined. With a wide range of smart connected devices by Dr Trust, now managing your health is easier than ever before. Download the Dr Trust 360 App and experience holistic healthcare solutions for all your lifestyle needs.

The Future Of Connected Healthcare

Choose from a wide range of smart devices by Dr Trust and stay connected with good health.



DrTrust 360
Manage Not Monitor

SMART SENSEI TECHNOLOGY

GET IT ON Google Play
Download on the App Store



Blood Pressure Monitors



Blood Glucose Monitors



Digital Weighing Scale

Our connected health solution – DrTrust 360

Aggregate

A unified app to track all the health metrics and vitals collected from various DrTrust devices

Access


Consult specialists from top hospitals, book diagnostics and lab services

Interact

Share real time health data with doctors nutritionist and health guardians

Engage

Personalised recipes, nutrition and workout videos targeted around user goals



1-MONTH	3-MONTH PLAN	6-MONTH PLAN
₹2999 ₹6200 Save over 51%	₹7999 ₹18600 Save over 57%	₹13999 ₹37200 Save over 62%
✓ 1 smart device FREE worth ₹ 4990	✓ 2 smart device FREE worth ₹ 6000	✓ 3 smart device FREE worth ₹ 12600
✓ Get a goal based diet plan	✓ Get a goal based diet plan	✓ Get a goal based diet plan
✓ Track calories with 1,00,000+ food database items	✓ Track calories with 1,00,000+ food database items	✓ Track calories with 1,00,000+ food database items
✓ Macronutrient tracking	✓ Macronutrient tracking	✓ Macronutrient tracking
✓ Dedicated health coach	✓ Dedicated health coach	✓ Dedicated health coach
✓ 2 personal calls - health coach	✓ 6 personal calls - health coach	✓ 12 personal calls - health coach
✓ Unlimited chat - health coach	✓ Unlimited chat - health coach	✓ Unlimited chat - health coach
SELECT ANY 1 PRODUCT	SELECT ANY 2 PRODUCTS	SELECT ANY 3 PRODUCTS
DrTrust 519 - Smart scale	DrTrust 519 - Smart scale	DrTrust 519 - Smart scale
DrTrust - iCheck Connect BP Monitor 118	DrTrust - iCheck Connect BP Monitor 118	DrTrust - iCheck Connect BP Monitor 118
DrTrust GlucoSMART 9004 with 25 strips	DrTrust GlucoSMART 9004 with 25 strips	DrTrust GlucoSMART 9004 with 25 strips
DrTrust - Healthpal smart watch 8002	DrTrust - Healthpal smart watch 8002	DrTrust - Healthpal smart watch 8002
COMING SOON ON iOS	COMING SOON ON iOS	COMING SOON ON iOS
Download the app	Download the app	Download the app

On our smart healthcare platform, Dr Trust 360, we have a series of value-added features:

Virtual Care & Telehealth

Dr Trust 360 now makes it easy to consult leading doctors at the comfort and convenience of your home via a video call. Our nutrition plans, combine behavioral psychology, technology, and live nutritionists coaching, helping our users in their weight management journey.




Health guardians

Add your health guardians so that they can be in the loop with the progress you make. Your health guardians shall receive whatsapp alerts at the right time when your readings are not in range.




Track your daily calories & Nutritional Support

Add and track your daily meals with our nutrition database with over 1,00,000+ Indian and global food items. Set your daily calorie intake goal and better understand your macro nutrient intake too. For better health management, platform provides nutritional support to our users with customised diet plan, calories tracking and dedicated nutritionist to guide our users achieved better results




During the quarter, we have added more value-added features:



SpO2 (Pulse Oximeter) – OCR camera


The app now allows the users to log their SpO2 readings using the Smart Sensei OCR camera. This will allow our range of Dr Trust SpO2 monitors to log and track it easily on the app

During the quarter, following UI / UX improvements done -




Weight Graph

Enabling users to view weighing scale results in graph form.




Home Screen

Personalized screen (based on the devices paired) where the User only sees the health tiles that are relevant to them.




Watch Faces

Users can download over 100 new watch faces for their smartwatch.



Activation Code

Coupon code added with a smart device purchase. This allows the users to enable their health plans remotely when they enter the app.




My Goals

Visual language improved for Users to get a clearer picture of their goals and how far they are from achieving it.

Chronic and Orthopedic Market

CHRONIC DISEASE PRODUCTS MARKET


(INR Cr)



Increasing Chronic diseases contribution to the deaths, higher spending power and availability of affordable healthcare products is driving the demand for chronic disease management products at their homes.

ORTHOPEDIC PRODUCTS MARKET

(INR Cr)



The growth in this market is primarily driven by the increasing incidence of chronic diseases, increasing accidents, rising geriatric population and increasing awareness for therapy.

Competitive Landscape

NUREÇA

OMRON



beurer



	NUREÇA	OMRON	PHILIPS	beurer	MI	Dr. Morepen®
Respiratory Care						
Nebulizer	√	√	√	√	x	√
Pulse Oximeter	√	x	x	√	x	√
Cardiac Care						
BP Monitor	√	√	x	√	x	√
Heart Rate Monitor	√	√	x	√	x	x
Diabetes Care						
Blood Glucometer	√	x	x	x	x	√
Niche Categories						
Massagers	√	√	x	√	x	x
Baby Care	√	x	√	√	x	x
Others						
Personal Scales	√	√	x	√	√	√
Thermometer	√	√	x	√	x	√
Vaporizer	√	x	x	√	x	√
Nutritional supplements	√	x	x	x	x	√

What Makes Nureca Different?

Product Quality

- International standards quality and design of the products

Regulatory Compliance

- Our products are manufactured to be safe, accurate, long-lasting and compliant to national and international regulations. Our chronic monitoring devices are USFDA approved.



Wide product range

- Nureca offers an entire bouquet of digital home healthcare devices

Price-value proposition

- Superior consumer price-value proposition with stringent quality control

Brand Loyalty

- Over the course of last 5 years, Nureca has generated a loyal customer base of over 8 million customers

Focused digital strategy

- Emphasis on 'Point of Sales' (POS) marketing via online channels; Videos on digital shelf and YouTube channel; Presence across multiple digital media; Strong emphasis on search engine optimisation (SEO).

Business Outlook

ADDING PRODUCTS AND CATEGORIES

- Strong focus on connected devices for remote patient monitoring
- Expansion into supplement and nutrition categories
- Create a pipeline of innovative healthcare and wellness products
- A strong customer base for cross-selling of different products

OFFLINE EXPANSION

- Increase tie-ups with modern retail brands, pharmacy chains, hospital chains and leading electronics chains.
- By the end of FY 22-23, the company plans to increase the distribution network.

MARKETING


- Increase online and offline advertising
- Increase influencer marketing
- The Company plans to leverage data analytics and artificial intelligence for higher conversions

With the launch of our connected devices eco system, we will leverage data science capabilities to empower more people living with chronic and lifestyle diseases to live better and healthier lives. Our software will analyze clinical data and apply iterative insights to our user's lifestyle to deliver a more personalized care experience. This will reinforce our theme of shifting India's healthcare sector from curative to preventive and further from preventive to pre-diagnostics. We will be one step closer to our goal of making a positive impact on the lifestyle and health of our esteemed users and eventually enhance the longevity of their lives. We are working with various partners and building capabilities to provide all healthcare services on our Dr. Trust 360 platform with affordable subscription rate which will change our business model from being product driven company to services driven company.



Shareholder Information

Shareholding as on 31st March 2022



Share Information as on 30th June 2022

NSE Ticker	NURECA
BSE Ticker	543264
IPO Listing Date	25 th February 2021
Market Cap (INR Cr)	990
Shares Outstanding	1,00,00,175
Industry	Healthcare

Thank .
You .

INVESTOR RELATIONS AT NURECA

Gurvikram Singh
cs@nureca.com

Office No. 101, Udyog
Bhavan, Sonawala Lane,
Goregaon East, Mumbai,
Maharashtra - 400063
Drtrust.in Drtrust360.com



Trust whats best for your family!